The yearly MetaSystems Distributor Meeting (DM), brought into life in 2002 as a platform to gather all international partners of MetaSystems and other members of the global MetaSystems family, just ended last week. The DM is being organized in turns by MetaSystems Headquarters, MetaSystems USA (MGI), and MetaSystems Asia. Since MGI is celebrating its 25th anniversary in 2018 they decided to choose a special location: Nassau, The Bahamas!
- Order Number
- Package Size
- 100 µl
In 2008 the World Health Organization (WHO) classification of tumors of hematopoietic
and lymphoid tissues introduced a new category for myeloid and lymphoid neoplasms
with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1. Many of these cases
present as a myeloproliferative neoplasm, usually with eosinophilia.
The hypereosinophilic syndrome may result from a novel fusion tyrosine kinase - FIP1L1/PDGFRA - that is a consequence of an interstitial chromosomal deletion which includes the CHIC2 gene region. The FIP1L1/PDGFRA fusion protein has been proven to be a therapeutic target of Imatinib. By triple-color FISH not only deletions involving CHIC2 but also translocations involving the 4q12 region can be detected.
- Chronic Myelogenous Leukemia and Myeloproliferative Neoplasms (CML/MPN)
- Acute Myelogenous Leukemia (AML)
Two blue-green-orange fusion signals (2BGO).
Aberrant Cell (typical results):
One blue-green-orange (1BGO) and one blue-green (1BG) fusion signal, indicating a deletion of CHIC2.
- Cools et al (2003) N Engl J Med 348: 1201-1214
- Griffin et al (2003) PNAS 100: 7830-7835
- Pardanani et al (2003) Blood 102: 3093-3096